FORT MYERS, Fla., Aug. 1, 2025 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that medical oncologist and hematologist Nikhita...
CHICAGO, Aug. 1, 2025 /PRNewswire/ -- Experity, the national leader in on-demand healthcare solutions, today announced the appointment of Bobby Ghoshal as President and Chief...
First-of-its-kind community learning platform and nonprofit initiative empowering leaders to advocate for systemic change worldwide
BOULDER, Colo., Aug. 1, 2025 /PRNewswire/ -- In response to today's...
PLEASANTVILLE, N.Y., Aug. 1, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Rowena Talusan-Dunn, PhD, LCAT, ATR is acknowledged as a Pinnacle Professional...
New Orders and Backlogs Contracting; Production Growing and Employment Contracting; Supplier Deliveries Faster; Raw Materials Inventories Contracting; Customers' Inventories Too Low; Prices Increasing; Exports...
Applications Open for National University of Singapore - Asian Institute of Digital Finance (NUS-AIDF) Certificate in FinTech & InsurTech for Odisha-based Students.
BHUBANESWAR, India, Aug....
HERSHEY, Pa., July 31, 2025 /PRNewswire/ -- Milton Hershey School (MHS) students enrolled in a college-level summer course have a unique opportunity to explore leadership concepts...
MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.
Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results
TORONTO, July 31, 2025 /CNW/ - Bayshore HealthCare (Bayshore) is proud to announce its Integrated Care Solutions (ICS) division has achieved Accredited with Commendation...